What you should know:
1. Takeda would likely sell the drugs it acquired when it purchased Nycomed in 2011. That drug portfolio could fetch about $3 billion.
2. People familiar with the matter listed Acino International AG, Avista Capital Partners, Stada Arzneimittel AG, EMS SA and Uniao Quimica Farmaceutica Nacional as potential buyers in emerging markets.
3. Takeda is also exploring deals in Western Europe with Advent International, Apollo Global Management and Cerberus Capital Management. The potential saleable assets in this deal are valued at $1.1 billion.
4. Takeda became one of the most indebted drugmakers in the world when it acquired Shire in January.
More articles on surgery centers:
Surgical Review Corp. awards dual accreditation to hand institute, ASC — 3 quick points
AAAHC releases 2019 quality roadmap
3 ASCs recently achieving accreditation
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
